Replay and MD Anderson Announce FDA Clearance of IND Application for First-in-Class PRAME-Targeted T-cell Receptor Natural Killer (TCR-NK) Cell Therapy for Hematological Malignancies

Replay and The University of Texas MD Anderson Cancer Center announced that the FDA has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for PRAME TCR/IL-15 NK (SY-307) for relapsed/refractory myeloid malignancies.